

**Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11)
Recombinant Antibody
Catalog # APR11038****Specification****Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) - Product Information**

Application	FC, E, FTA
Primary Accession	Q9UPY5
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) - Additional Information**Target/Specificity**
SLC7A11**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) - Protein Information****Name** SLC7A11 ([HGNC:11059](#))**Function**
Heterodimer with SLC3A2, that functions as an antiporter by mediating the exchange of extracellular anionic L-cystine and intracellular L-glutamate across the cellular plasma membrane (PubMed:11133847, PubMed:11417227, PubMed:14722095, PubMed:15151999, PubMed:34880232, PubMed:35245456, PubMed:35352032). Provides L-cystine for the maintenance of the redox balance between extracellular L- cystine and L-cysteine and for the maintenance of the intracellular levels of glutathione that is essential for cells protection from oxidative stress (By similarity). The transport is sodium-independent,

electroneutral with a stoichiometry of 1:1, and is driven by the high intracellular concentration of L-glutamate and the intracellular reduction of L-cystine (PubMed:11133847, PubMed:11417227). In addition, mediates the import of L-kynurenine leading to anti-ferroptotic signaling propagation required to maintain L-cystine and glutathione homeostasis (PubMed:35245456). Moreover, mediates N-acetyl-L-cysteine uptake into the placenta leading to subsequently down-regulation of pathways associated with oxidative stress, inflammation and apoptosis (PubMed:34120018). In vitro can also transport L-aspartate (PubMed:11417227). May participate in astrocyte and meningeal cell proliferation during development and can provide neuroprotection by promoting glutathione synthesis and delivery from non-neuronal cells such as astrocytes and meningeal cells to immature neurons (By similarity). Controls the production of pheomelanin pigment directly (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein. Cell projection, microvillus membrane; Multi-pass membrane protein. Note=Localized to the microvillous membrane of the placental syncytiotrophoblast.

Tissue Location

Expressed in term placenta and primary term cytotrophoblast (PubMed:34120018). Expressed mainly in the brain, but also in pancreas (PubMed:11417227).


Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) - Images





Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-SLC7A11 Reference Antibody (Agilvax Patent Anti-Slc7A11) is more than 95%, determined by SEC-HPLC.